Al Mutair: Overview of Clinical Outcome and Therapeutic Effectiveness of Favipiravir in Patients with COVID-19 Admitted to Intensive Care Unit, Riyadh, Saudi Arabia

Al Mutair, 538 patient favipiravir late treatment study: 7% lower mortality [p=0.49], 9% higher ARDS [p=0.63], 34% higher ICU admission [p=0.001], and 37% longer hospitalization [p=0.001] https://c19p.org/almutair

copied to clipboard

Overview of Clinical Outcome and Therapeutic Effectiveness of Favipiravir in Patients with COVID-19 Admitted to Intensive Care Unit, Riyadh, Saudi Arabia

Al Mutair et al., Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.01.013

15 Feb 2022 Source PDF Share Tweet

Retrospective 269 favipiravir ICU patients in Saudi Arabia and 269 matched controls receiving different treatments, showing no significant difference.

risk of death, 7.0% lower, RR 0.93, p = 0.49, treatment 119 of 269 (44.2%), control 128 of 269 (47.6%), NNT 30.

risk of ARDS, 8.6% higher, RR 1.09, p = 0.63, treatment 76 of 269 (28.3%), control 70 of 269 (26.0%), severe ARDS.

ICU time, 33.7% higher, relative time 1.34, p = 0.001, treatment 269, control 269.

hospitalization time, 36.6% higher, relative time 1.37, p = 0.001, treatment 269, control 269.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Al Mutair et al., 2/15/2022, retrospective, Saudi Arabia, Middle East, peer-reviewed, 14 authors, study period April 2020 - March 2021, this trial compares with another treatment - results may be better when compared to placebo.

All Studies Meta Analysis

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Antiandrogens	(meta)	Lactoferrin	(meta)
Aspirin	(meta)	Melatonin	(meta)
Bamlaniv../e..	(meta)	Metformin	(meta)
Bebtelovimab	(meta)	Molnupiravir	(meta)
Bromhexine	(meta)	N-acetylcys..	(meta)
Budesonide	(meta)	Nigella Sativa	(meta)
Cannabidiol	(meta)	Nitazoxanide	(meta)
Casirivimab/i..	(meta)	Paxlovid	(meta)
Colchicine	(meta)	Peg.. Lambda	(meta)
Conv. Plasma	(meta)	Povidone-Iod..	(meta)
Curcumin	(meta)	Probiotics	(meta)
Diet	(meta)	Proxalutamide	(meta)
Ensitrelvir	(meta)	Quercetin	(meta)
Ensovibep	(meta)	Remdesivir	(meta)
Exercise	(meta)	Sleep	(meta)
Famotidine	(meta)	Sotrovimab	(meta)
Favipiravir	(meta)	Tixagev../c..	(meta)
Fluvoxamine	(meta)	Vitamin A	(meta)
Hydroxychlor..	(meta)	Vitamin C	(meta)
Iota-carragee..	(meta)	Vitamin D	(meta)
Ivermectin	(meta)	Zinc	(meta)

Other Treatments		Global Adoption